Target intelligence / Profile preview

Particularly Interesting New Cysteine-Histidine-rich protein 1 (PINCH-1) (PINCH-1)

Target
PINCH-1
Molecular classification
Adaptor protein, LIM domain protein
01

Overview

Particularly Interesting New Cysteine-Histidine-rich protein 1 (PINCH-1), also known as LIMS1, is a highly conserved adaptor protein composed of five LIM domains that facilitate diverse protein-protein interactions. It is a core component of the heterotrimeric ILK-PINCH-Parvin (IPP) complex, which serves as a critical bridge between the extracellular matrix and the actin cytoskeleton by interacting with integrin-linked kinase (ILK). Through this complex, PINCH-1 regulates essential cellular processes including adhesion, spreading, migration, and survival signaling, primarily by modulating the PI3K/AKT and Ras/MAPK pathways. Beyond its role at focal adhesions, PINCH-1 can also translocate to the nucleus to act as a transcriptional regulator, particularly in specialized cells like podocytes. In pathological contexts, PINCH-1 is frequently overexpressed in various malignancies, including pancreatic, lung, and breast cancers, where it promotes tumor growth, epithelial-to-mesenchymal transition (EMT), and metastasis. It also plays a significant role in the progression of fibrotic diseases, such as renal and pulmonary fibrosis, by promoting fibroblast activation and survival. While no drugs targeting PINCH-1 are currently FDA-approved, it is an active area of preclinical research. Experimental strategies include the use of siRNAs delivered via nanocarriers and the development of small-molecule inhibitors to disrupt the IPP complex. Recent studies also suggest its potential as an immunotherapeutic target, where blocking PINCH-1 may enhance the innate immune system's ability to eliminate cancer cells by acting as a "don't-eat-me" signal.

Other names
LIMS1PINCHPINCH1LIM and senescent cell antigen-like domains 1Renal carcinoma antigen NY-REN-48Senescent cell antigen
02

Biological functions

Cell adhesionCell migrationCell survivalIntegrin signalingMechanotransductionProtein-protein interactionTranscriptional regulation
03

Disease associations

CancerFibrosisCardiovascular diseaseInfection
04

Safety considerations

Embryonic lethality (essential for early development)Impairment of normal cell-matrix adhesionPotential for epidermal detachment or hair lossRole in maintaining normal podocyte and cardiomyocyte function
05

Interacting drugs

Anti-LIMS1 siRNA (experimental)

1 more in the full profile.

06

Biomarkers

LIMS1 protein expression levelTumor LIMS1 mRNA levelsAdvanced TNM stage association

Beyond the preview

Go deeper on Particularly Interesting New Cysteine-Histidine-rich protein 1 (PINCH-1) (PINCH-1).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Full profile access

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Full profile access

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Full profile access

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Full profile access

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Full profile access

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Full profile access

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Particularly Interesting New Cysteine-Histidine-rich protein 1 (PINCH-1) (PINCH-1).

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call